Table 1 - uploaded by Samia A. Abdul-Rahman
Content may be subject to copyright.
Contexts in source publication
Context 1
... age among group (1) was 67.30 ± 6.82 yr, group (2) was 65.83 ± 5.96 yr and among group (3) was 67.10 ± 9.40 years. Males represented 37.8% (n = 34) while females represented 62.2% (n = 56) of the study sam- ple ( Table 1). As for comorbidities in group (1), 40% (n = 12) had ischemic heart disease and 16.6% (n = 5) had cerebrovascular disease and all of them had hy- pertension. ...
Context 2
... and diastolic blood pressures, weight and hs- CRP levels showed statistically significant difference be- tween group (1), (2) and (3) (P value ≤ 0.001, < 0.001, 0.030, < 0.001 respectively) being all highest among group (1) and lowest among group (3) ( Table 1). Post hoc Bonferroni test revealed that the significant differ- ences in systolic and diastolic blood pressures and weight were only between those of group (1) and group (3), while the significant differences in hs-CRP levels were between groups (1) and (3) (P value < 0.001), (2) and (3) (P value < 0.001), and (1) and (2) (P value < 0.021). ...
Context 3
... hoc Bonferroni test revealed that the significant differ- ences in systolic and diastolic blood pressures and weight were only between those of group (1) and group (3), while the significant differences in hs-CRP levels were between groups (1) and (3) (P value < 0.001), (2) and (3) (P value < 0.001), and (1) and (2) (P value < 0.021). Hs-CRP levels were highest in group (1) (1266.67 ± 392.96 mg/dl) followed by group (2) (991.6 ± 448.12 mg/dl) then group (3) (420.43 ± 303.11 mg/dl) ( Table 1). ...
Similar publications
Background
Estimation of the epidemiological burden of carotid atherosclerosis can serve as a basis for prevention and management of cardiovascular disease. We aimed to provide the first estimation on the prevalence, number of cases, and risk factors for carotid atherosclerosis in the general population globally and regionally.
Methods
In this sys...
Citations
... They also had signifi cantly higher serum CRP, TNF-alpha and IL-6, which is in agreement with previous studies, although not all these biomarkers were found to be elevated in all previously published papers. Higher levels of CRP, especially hs-CRP were found by many authors (16,17). Increased levels of CRP have been demonstrated to represent a higher risk of cardiovascular events in the group of patients with PAD (14). ...
Introduction:
Peripheral arterial disease (PAD) is a common condition due to atherosclerosis with high prevalence in population over 55 years. Although its pathophysiology is well recognized, the role of inflammatory markers is still not fully known.
Objectives:
The aim of the study was to assess the relation of C-reactive protein (CRP), tumor necrosis factors-alpha (TNF-alpha) and interleukin-6 (IL-6) to ankle-brachial index (ABI) and metabolic variables in patients with PAD. The second aim was to find the most significant humoral predictor of ABI.
Patients and methods:
The study groups consisted of 55 patients (36 men and 19 women) diagnosed with PAD (age 63.65 ± 6.11 years) and 34 control subjects (7 men, 27 women) of average age 59.88 ± 6.10 years with ABI > 0.9. Blood samples were analyzed for glycaemia, lipid profile and inflammatory markers (CRP, TNF-alpha and IL-6).
Results:
A significantly higher serum total cholesterol (p = 0.04), triglycerides (p = 0.005) and lower HDL cholesterol (p < 0.0001) were found in the PAD group as compared to controls. Patients with PAD had significantly higher serum glucose (p = 0.008), CRP (p = 0.0044), IL-6 (p < 0.0001) and TNF-α (p < 0.0001) in comparison to controls. In a multiple linear regression analysis among variables log IL-6 and log HDL cholesterol were most significantly related to ABI (LW 4.75 for log IL-6, LW 4.016 for log HDL cholesterol, respectively, p < 0.01) in all subjects.
Conclusions:
We conclude that among traditional and humoral risk factors IL-6 is the strongest predictor of ABI. HDL cholesterol is also significant and strong predictor of decreased ABI and could be a potential biomarker of PAD in patients using lipid lowering drugs (Tab. 1, Ref. 31).
